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Background: Blockage of the Na+/Ca2+ exchanger (NCX) is used to determine the role
of NCX in arrhythmogenesis. Trisulfated heparin disaccharide (TD) and Low Molecular
Weight Heparins (LMWHs) can directly interact with the NCX and accelerate its activity.
Objective: In this work, we investigated the antiarrhythmic effect of heparin
oligosaccharides related to the NCX activity.
Methods: The effects of heparin oligosaccharides were tested on the NCX current
(patch clamping) and intracellular calcium transient in rat cardiomyocytes. The effects
of heparin oligosaccharides were further investigated in arrhythmia induced in isolated
rat atria and rats in vivo.
Results: The intracellular Ca2+ concentration decreases upon treatment with either
enoxaparin or ardeparin. These drugs abolished arrhythmia induction in isolated atria. The
NCX antagonist KB-R7943 abolished the enoxaparin or ardeparin antiarrhythmic effects
in isolated atria. In the in vivomeasurements, injection of TD 15min both before coronary
occlusion or immediately after reperfusion, significantly prevented the occurrence of
reperfusion-induced arrhythmias (ventricular arrhythmia and total AV block) and reduced
the lethality rate. The patch clamping experiments showed that, mechanistically, TD
increases the forward mode NCX current.
Conclusion: Together, the data shows that heparin oligosaccharides may constitute a
new class of antiarrhythmic drug that acts by accelerating the forward mode NCX under
calcium overload.
Keywords: arrhythmia, low molecular weight heparin, trisulfated heparin disaccharide, sodium-calcium
exchanger, calcium overload
INTRODUCTION
Many authors have studied the potential antiarrhythmic effect of NCX blockers by targeting the
role of the NCX in arrhythmogenesis (1, 2). Theoretically, the undesirable effects of blocking Ca2+
eﬄux on NCX activity could be limited by the predominant inhibition of its reverse mode over the
forwardmode. KBR-7943 was the first drug from a generation of NCX blockers with reportedmode
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selectivity. Such drug was eventually followed by SEA-0400 (3–
5), which is more potent and more selective for NCX and,
most recently, by SN-6 (6) and ORM-10962 (7). Nonetheless,
occasionally these drugs are not useful for NCX function studies,
but they may be appropriate as part of an antiarrhythmic strategy
(6, 7).
As mentioned, blockage of NCX is a common tool used to
target the role of NCX in arrhythmogenesis. On the other hand,
it has been shown that heparin disaccharides accelerate NCX
instead of blocking it which opens new perspectives to evaluate
arrhythmogenesis or other Ca2+ overload situations. Shinjo and
colleagues observed that cumulative doses of trisulfated heparin
disaccharide (TD) decrease cytosolic Ca2+ levels in smooth
muscle cell lines derived from the rabbit aorta (8). They have also
shown that heparin oligosaccharides directly interact with the
NCX and accelerate the NCX activity. Recently, it was shown that
TD decreases liver cell damage and increases hepatic tolerance
to ischemia/reperfusion injury by calcium extrusion in Ca2+
overload conditions (9).
In the present work, we investigated how heparin
oligosaccharides would affect arrhythmogenesis in isolated
rat atria and rats in vivo, and NCX currents and intracellular
calcium in isolated cardiomyocytes. Here, we show for the
first time that Low Molecular Weight Heparins (LMWHs) and
TD have significant antiarrhythmic activity mediated by the
acceleration of the NCX forward mode activity.
METHODS
Isolated Atrium
The isolated rat atrium preparation and the electric field
stimulation (EFS) induced tachyarrhythmia followed what was
previously described (10). The isolated heart was placed in a
vial with a Krebs-Henseleit solution (KH perfusate) to allow
blood pumping and right atrium isolation. The KH perfusate
had the following composition: 126.4mM NaCl, 4.6mM KCl,
1.2mM KH2PO, 1.2mM MgSO4, 13.6 NaHCO3, 1.5mM CaCl2,
11.11mM glucose, pH 7.4 at 36.5◦C, saturated with 95% O2 plus
5% CO2.
The EFS protocol (rapid pacing - 250 biphasic voltage
pulses of 66.7Hz; 5ms duration; 2-fold threshold strength) and
electrogram detection of isolated atria were performed using
an electric stimulator (S48–Stimulator, Grass; Inst. Division,
Astro-Med Inc; W. Warwick, RI, USA) and an amplifier (Iso-
Dam8; World Precision Instruments, Inc., Sarasota, FL, USA).
Both devices were connected to a commercial acquisition system
(AqDados R© 7.02; Lynx Tecn. Electr. Ltda., São Paulo, SP, Brazil).
Arrhythmia inductions were performed in isolated right atria
removed either from rats without any pharmacological treatment
or from rats previously treated (1 h) with an intraperitoneal
injection of enoxaparin at doses of either 0.7 or 5.7 mg/kg.
The effects of 50µM KB-R7943 (an inhibitor of the reverse
NCX) and/or 100µM enoxaparin (or ardeparin) were evaluated
on EFS-induced tachyarrhythmia in the isolated right atria.
Tachyarrhythmia induction by rapid pacing was performed 30–
40min after drug treatment in KH perfusate. These drug studies
were performed 30min after atrial tachyarrhythmia induced by
rapid pacing and resumed to the normal rate (control); the
arrhythmias sustained for at least 5min.
In Vivo Experiments (Ischemia-Reperfusion
Method)
A control group of rats (treated with saline solution only)
was initially tested to identify any lethality in all types of
arrhythmias induced by the ischemia-reperfusion procedure.
Trisulfated heparin disaccharide (TD), O-(4-deoxy-hex-4-
enopyranosyluronic acid 2-sulfate) -(1→ 4)-2-sulfamino-D-
glucose 6-sulfate was administered intravenously (IV; 0.025
mg/kg). TD was prepared as previously described (8). Its purity
and structure integrity was evaluated by Nuclear Magnetic
Resonance spectroscopy.
The experimental protocol for each route of drug
administration is illustrated in Scheme 1. The ECG was
recorded throughout the entire procedure, including prior to
any injection.
In Vivo Ischemia-Reperfusion Method for
Arrhythmia Induction
The animal preparation followed the methods described by
Guarini and colleagues (11). Rats anesthetized with urethane
(1.25 g/kg IP) were immobilized in the supine position.
Polyethylene catheters were inserted into a common carotid
artery and a femoral vein. The arterial catheter was connected
to a transducer for the recording of the mean arterial pressure
on a microcomputer acquisition system (same setup described in
the “Isolated Atrium” item). Drug administration was performed
via the venous catheter. After opening the rat chests by left
thoracotomy, the heart was exteriorized by pressure on the
abdomen. A ligature was made close to the origin of the left
coronary artery using silk suture. The ends of the silk suture used
in the ligature were passed through a polyethylene tube. Then,
the heart was in the chest cavity such that the ligature ends were
exteriorized. Reperfusion was performed after 10min of coronary
SCHEME 1 | Diagram of the experimental protocol for each route of drug
administration in the rat. IV: intravenous.
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occlusion by cutting the suture externally to the polyethylene
tube. The animals were then further monitored during 2 h for
evaluation of lethality and the occurrence of arrhythmias.
The heart rate and incidence of post ischemia-reperfusion-
induced arrhythmias such as ventricular fibrillation (VF)
and ventricular tachycardia (VT) were evaluated at control
condition (no drug) or at presence of Trisulfated heparin
disaccharide (TD), O-(4-deoxy-hex-4-enopyranosyluronic acid
2-sulfate) -(1→ 4)-2-sulfamino-D-glucose 6-sulfate. TD was
administered intravenously (0.025 mg/kg) 5min prior ischemia
(pre-treatment) or in the beginning of reperfusion (post-
treatment). The ECGs measurements were performed according
to the Lambeth Conventions (12).
The control group (no drug treatment) was compared
to the drug-treated groups using ANOVA. The incidence of
arrhythmias, such as ventricular or atrial fibrillation, as well as
ventricular tachyarrhythmia, was compared with Fisher’s Exact
Test in all groups.
All animal procedures conform to the Guide for the Care
and Use do Laboratory Animals, and were approved by The
Committee of Ethical in Animal Research of either University
of Mogi das Cruzes - UMC (isolated rat atrium) or Federal
University of São Paulo–UNIFESP (in vivo rats).
Patch Clamp Experiments
The patch clamp protocol was designed for the recording of
Na+/Ca2+ exchange current (NCX current) from isolated rat
ventricular myocytes. The recordings occurred in the absence
or presence of different TD concentrations. Adult rat myocytes
were obtained from ventricles. The patch clamp experiments
were performed at Zenas Technologies LLC (1441 Canal St. New
Orleans, LA 70112).
Current Measurements and Analysis
Currents were measured using the whole-cell variant of the
patch clamp method. Experiments were performed at 24 ±
1◦C. Glass pipettes were pulled from borosilicate glass by a
horizontal puller (Sutter Instruments, USA), then fire polished
to produce tip openings of 1–2µm. An Axopatch 1B amplifier
(Axon Instruments, Foster City, CA) was used for whole-cell
voltage clamping. The voltage clamp pulses and data acquisition
were controlled by a computer running pClamp software (ver 9.2
Axon Instruments). After rupture of the cell membrane (entering
whole-cell mode), current amplitude and kinetics were allowed to
stabilize (3–5min) before starting the experiments. The voltage
clamp protocol for NCX current consisted of slow-ramp pulses
applied from −120 to +80mV at 0.09 V/s and 0.1Hz. The
current which was sensitive to 5mM Ni2+ was taken as the
NCX current. The NCX current was obtained by subtracting
the currents recorded in perfusate with Ni2+ (NCX blocker
NiCl2 added at the end of each experiment) from the currents
recorded in Ni2+-free perfusate. The holding potential was
−40mV to block T-type Ca2+ and Na+ currents. Three different
concentrations of intracellular Ca2+ (Cai; in nM: 300, 400, 600)
were used in separate experiments. One drug concentration (TD:
10, 30, or 100µM) was applied per cell (n = 3). The perfusate
solution (compounds from Sigma-Aldrich Chemical Company)
contained (in mM): NaCl 135, CsCl 10, MgCl2 1, CaCl2 2, HEPES
10, Dextrose 10; pH 7.4 adjusted using Cs-OH. The solution
was K+-free to block inward rectifier K+ and Na+-K+-ATPase
currents. The solution also contained (in µM/L): nifedipine
0.5, nifumic acid 100, ouabain 10 and 0.001 thapsigargin to
block L-type Ca2+, Cl−, Na+-K+-ATPase and sarco/endoplasmic
reticulum Ca2+ ATPase (SERCA) currents, respectively. The
internal solution (pipette) contained (in mmol/L): CsCl 136,
NaCl 10, Aspartate 42,MgCl2 3, HEPES 5, TEA-Cl 20,MgATP 10;
pH of 7.2 adjusted using Cs-OH andCaCl2 adjusted with BAPTA.
Raw data and mean ± SEM are given. Data is presented as %
change of current amplitude. This was measured as peak current
increase in the presence of the tested compound relative to the
current amplitude before treatment (control). Each cell served as
its own control.
Calcium Transient Measurements
The fluorometric analysis of cytosolic Ca2+ levels in rat
cardiomyocytes was performed according to the method
proposed by Lopes and colleagues (13). The effects of enoxaparin
(Clexane R©, Sanofi-Aventis) and ardeparin (Normophilo R©,
Wyeth-Ayerst Laboratories) in intracellular Ca2+ transient were
studied in a suspension of cardiomyocytes stimulated with drugs
capable of either increasing Ca2+ influx through the direct
activation of L-type VDCC (Bay K 8644) or promoting the
release of Ca2+ from the sarco/endoplasmic reticulum through
the activation of SERCA by either ryanodine or caffeine (14).
In assays with Bay K 8644, nifedipine, the selective blocker of
L-type VDCC, was used to inhibit the influx of Ca2+ mediated by
these channels. In assays with ryanodine and caffeine, a selective
blocker of the SERCA, was used to inhibit the uptake of Ca2+ by
SERCA.
RESULTS
Isolated Atrium
Figure 1 shows typical electrogram records of the EFS-protocol
inducing arrhythmia in the right atrium (left upper panel)
and enoxaparin (10µM) preventing arrhythmia induction (left
lower panel; same atrium). KB-R7943 treatment (50µM) failed
to prevent arrhythmia induction in the right atrium after
EFS-protocol (right upper panel). The antiarrhythmic effect of
enoxaparin was not observed after EFS-protocol application
when KB-R7943 was present (right lower panel). As compared
to the control, the sinus rate prior to the EFS-protocol was
decreased in the presence of 50µMKB-R7943.
LMWHs (enoxaparin, N = 20; ardeparin, N = 20) abolished
atrial arrhythmia induction in all tests. Neither unfractionated
heparin (N=6) nor KB-R7943 (N = 6) abolished atrial
arrhythmia in all tests. Pre-treatment with KB-R7943 abolished
the antiarrhythmic effect of enoxaparin (N = 6) and ardeparin
(N = 5), suggesting that the antiarrhythmic effect of these
LMWHs requires functional NCX.
The intraperitoneal injection of enoxaparin in rats resulted in
an antiarrhythmic effect in the isolated atrium. The arrhythmia
induction rates (number of atria in which arrhythmia was
induced/total number of atria) for the control condition and
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enoxaparin doses of 0.7mg/kg and 5.7mg/kg were 30/30, 0/5, and
0/5, respectively. The arrhythmia induction rates in the presence
of enoxaparin were significantly different from that of the control
condition (p < 0.05; X2-test).
Animal Studies
Table 1 summarizes the effect of intravenous (IV) pre-treatment
with TD and IV post-treatment with TD on arrhythmias induced
by post-ischemia reperfusion.
Coronary reperfusion following a 10min occlusion caused the
occurrence or worsening of ventricular arrhythmias (ventricular
extrasystoles, ventricular tachycardia, ventricular fibrillation, and
Torsades de Pointes) in 28 out of 33 (85%) control rats and total
AV-blocking in 26 out of 33 (79%) control rats. The lethality
under such conditions was high (23/33, 70%).
Treatment with the TD (0.025 mg/kg; IV) 15min prior
coronary occlusion significantly prevented reperfusion-induced
arrhythmias (ventricular arrhythmias and total AV-blocking)
and reduced the lethality rate. Injection of TD (0.025 mg/kg;
IV) at the early stages of reperfusion significantly prevented
the occurrence of reperfusion-induced arrhythmias (ventricular
arrhythmias and total AV-blocking) and reduced the lethality
rate. Hence, the heparin trisulfated disaccharide is the minimum
heparin fragment that is able to prevent severe arrhythmias and
decrease the lethality from cardiac arrhythmias in rats.
Effect of TD Pre-treatment in ECG Intervals
Pre-treatment with TD (0.025 mg/kg; IV) did not affect the
normal ECG parameters of the control animals (Table 2). The
normal PR intervals were unchanged by TD pre-treatment,
suggesting that TD not disturb normal A-V conduction. The
normal QT intervals were also unchanged by TD pre-treatment,
suggesting that TD not disturb the normal time of ventricular
repolarization. Finally, TD pre-treatment did not change the
normal RR intervals, further suggesting that TD not alter normal
heart rate.
Calcium Transients
As shown in Figure 2, Ca2+ transients induced by Bay-K was
decreased by enoxaparin (Figure 2A) and ardeparin (Figure 2B)
(N = 5; p < 0.05 for each LMWH). Nifedipine did not block
TABLE 1 | Summary of ischemia/reperfusion data.
Groups N Ventricular
Arrhythmia
Total
AV-Block
Death
Control 33 28/33a 26/33a 23/33a
Pre-treatment (TD
0.025 mg/kg)
10 3/10*
(P = 0.0020)
1/10*
(P = 0.0002)
0/10*
(P < 0.0001)
Post-treatment
(TD 0.025 mg/kg)
10 3/10*
(P = 0.0020)
1/10*
(P = 0.0002)
0/10*
(P < 0.0001)
aThe numbers in columns 3, 4, and 5 represent the proportions of arrhythmia or death
events in relation to total number of rats in a given group. *Data were considered to be
statistically significant by Fisher’s Exact Test (The two-sided P-values < 0.05).
TABLE 2 | Summary of ECG intervals data.
Group N ECG INTERVAL (ms)
RR PR QT
Control 30 189 ± 6 52 ± 2 70 ± 1
TD 0.025 mg/kg 10 203 ± 13
(P = 0.2278)
51 ± 1
(P = 0.1189)
71 ± 1
(P = 0.1996)
ECG intervals are expressed as the means ± standard error. ECG intervals (either RR or
PP or QT) from the control group were not significantly different from those of the TD
Group (ANOVA; The two-sided P-values > 0.05).
FIGURE 1 | Typical electrogram records of isolated rat atria submitted to the electric field stimulation (EFS) protocol. The effect of the EFS-protocol on atrial response
was studied in the absence of any drug treatment (control, Left upper) as well as in the presence of 50µM KB-R7943 alone (Right upper), 10µM enoxaparin alone
(Left lower) and the simultaneous presence of 50µM KB-R7943 and 10µM enoxaparin (Right lower). The sinus rates (Hz) prior to the EFS-protocol were 3.7, 3.6,
0.9, and 1.2 in control, enoxaparin alone, KB-R7943 alone and enoxaparin + KB-R 7043 groups, respectively. Accordingly, the atrial rates (Hz) following the
EFS-protocol for these groups were 25, 5.8, 25, and 25, respectively.
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FIGURE 2 | (A,B) Calcium transients induced by Bay-K in either the absence (control) or presence of enoxaparin (ENOX 1µM) or ardeparin (ARD 1µM). (C) Calcium
transient induced by Bay-K in the presence of either nifedipine alone (NIF 1µM) or simultaneous presence of 1µM NIF and 1µM ENOX. (D,E) Calcium transients
induced by the caffeine-ryanodine-thapsgargin cocktail (CRT) in either the absence (control) or presence of 1µM ENOX or 1µM ARD.
the effect of enoxaparin on Ca2+ transients (Figure 2C), showing
that enoxaparin is not dependent on voltage-dependent calcium
channels (N = 5; p < 0.05). Additionally, the Ca2+ transients
induced by the CRT were reduced by enoxaparin (Figure 2D)
and ardeparin (Figure 2E) (N = 5; p < 0.05 for each LMWH).
Patch Clamping
Figure 3 shows the effect of TD on NCX currents. The
ability of TD to activate the NCX was characterized at 3 Cai
concentrations: 600, 400, and 300 nM. Such ability occurred
essentially at forward mode NCX (Ca2+ eﬄux), as the NCX
currents did not change above the NCX reversal potential. The
effects were similar at lower Cai concentrations, although the
amplitude of the forward mode NCX current was reduced.
DISCUSSION
In this work, we have presented experimental data that show the
participation of NCX on the antiarrhythmic effect of LMWHs
and trisulfated heparin disaccharide. The antiarrhythmic effects
observed with these compounds were shown to both reverse or
prevent arrhythmias.
The patch clamping experiments showed that the TD
concentration-dependently increases the inward NCX current at
Cai concentrations ranging from 300 to 600 nM. Thus, it was
verified that TD can activate the forward mode NCX current
(i.e., promote Cai eﬄux) in isolated rat cardiac myocytes. Such
effect increases Ca2+ extrusion from the cell, as suggested by the
results of calcium transient experiments. Previously, it was shown
in smooth cells that TD and enoxaparin accelerate intracellular
Ca2+ by activating the NCX (8). This indicates that the decrease
in cytosolic Ca2+ in cardiomyocytes produced by TD or LMWHs
is influenced by the enhancement of forward mode NCX activity,
which is supported by the fact that the NCX mediates Ca2+
homeostasis similarly in many cell types (15).
Both TD and LMWHs have antiarrhythmic effects by acting
in a variety of targets involved in the regulation of cardiomyocyte
contraction (16). This hypothesis is corroborated by other results
presented by Barry and colleagues (17), who observed that
heparin disaccharides stimulate Ca2+ extrusion and reduce Ca2+
overload in pig cardiomyocytes via NCX activation and other
molecule targets, such as L-type Ca2+ channels or Na+ channels.
This suggests that TD and LMWHs are (at least) partially acting
as an antiarrhythmic drug by reducing intracellular Ca2+ loading
via NCX activation. As a result, we investigated a possible
antiarrhythmic effect of TD and LMWHs in isolated atria and
in rats in vivo, using experimental approaches in which Ca2+
overload is involved with the arrhythmogenic mechanism.
The antiarrhythmic effects of LMWHs were evaluated in
isolated atria under rapid-pacing induced arrhythmia. This
methodology has been used to evaluate aging and to test drugs
that affect cholinergic modulation on atrial tachyarrhythmia
vulnerability (9). As Ca2+ overload is enhanced by fast rates (18),
enoxaparin and ardeparin were both evaluated as antiarrhythmic
drugs to prevent atrial tachyarrhythmia. The antiarrhythmic
effect of these LMWHs occurred only if NCX was fully functional
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FIGURE 3 | Effects of trisulfated heparin disaccharide (TD) on the NCX current (NCX) recorded from acutely isolated rat ventricular myocytes at various Cai
(A: 300 nM; B: 400 nM and C: 600 nM). The graph (D) is % change obtained by dividing the current amplitude value at a given voltage for a given test compound
concentration by the current value recorded in the absence of test compound (control).
(i.e., not having reverse-mode blocked by KB-R7943) indicating
a crucial role of the exchanger (likely due to Ca2+ overload
reduction) on this effect.
The in vivo studies show that both pre- and post-treatment
with TD significantly reduced the incidence of ventricular
arrhythmias and total atrioventricular block (TAVB) as well
as lethality, which was zero. The influence of an ultra-low
molecular weight heparin (Oligo-H, m.w. 2 kDa) on ventricular
arrhythmias and lethality using equivalent in vivo methodology
has been previously reported (11). They concluded that LMWHs
significantly reduce the consequences of heart reperfusion. In
the present work, we observed that the IV treatment of TD
effectively prevents lethal arrhythmia and reduces animal death
after arrhythmia induction.
The results show that the pre-treatment with TD (0.025
mg/kg) injected IV 15min prior coronary occlusion
significantly prevents the elevation of QT intervals induced
by ischemia/reperfusion procedures. As intracellular Ca2+
dysregulation is a common thread of calcium-mediated
arrhythmias and ECG alterations (19), it is reasonable to suggest
that the effects of the TD IV treatment mitigated the Ca2+
overload involved with the NCX activation.
A limitation of the present study is the relatively small sample
used in the experiments. However, the number of animals in
each group was the minimum necessary and sufficient to achieve
statistical significance shown in the results, as recommended by
animal ethics committees (20).
The development of non-pharmacologic therapies to
the treatment of cardiac arrhythmias, such as targeted
ablation of arrhythmogenic tissues (21) and implantable
cardioverter defibrillators (22), occurred mainly due to the
low efficacy (between 30 and 60%) of antiarrhythmic agents in
suppressing the most common arrhythmia, atrial fibrillation,
and to the proarrhythmic potential of antiarrhythmic agents.
However, despite the current success of ablative therapy and
implantable defibrillators, the need is still pressing for new
antiarrhythmic drugs (23). Indeed, antiarrhythmic drug use,
such as amiodarone and lidocaine, has been preconized in
patients with out-of-hospital cardiac arrest (OHCA) since
bradyasystole and pulseless electrical activity (PEA), called
non-shockable rhythms, may evolve to shockable ventricular
fibrillation or pulseless ventricular tachycardia (VF/VT) during
resuscitation in up to 25% of patients with OHCA (24, 25).
Nevertheless, in amiodarone therapy, there is a higher risk of
bradycardic events (26) and lack of benefit on overall mortality
(27).
Thus, the potential to cause harm through pro-arrhythmic
effects has placed constraints on the use of many existing
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antiarrhythmic drugs and restricted the release of new drugs
for clinical use (28). Here, our data is showing that the new
accelerator of the NCX forward mode TD efficiently suppresses
Torsades de Pointes and ventricular tachycardia (VF/VT) after
lethal arrhythmia induction in rats without developing major
bradycardic events. Also, it is important to mention that
the trisulfated heparin disaccharide, the minimum heparin
fragment, has a negligible anticoagulant activity, showing that
the antiarrhythmic activity of heparin oligosaccharides may be
tailored for conditions in which anticoagulation therapy/effects
is undesirable.
Together, our data indicate that the antiarrhythmic effects
of TD and LMWHs are related to intracellular Ca2+ overload
attenuation by the NCX acceleration. Thus, as the stimulation
of the forward mode NCX activity reduces cytosolic Ca2+
and exert a therapeutic action (29, 30), the data provide
strong evidence that the heparin oligosaccharides, even
those with very low anticoagulant activity as depicted by
TD, may constitute a new class of antiarrhythmic drug
that acts mechanistically by accelerating the NCX forward
mode.
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